Phase II clinical trial - Recherches "plusieurs pathologies"

Recherches "plusieurs pathologies"
Essai clinique fermé
Public cible
A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repair-deficient or platinum-sensitive solid tumors
Description de l'essai
This research will assess the effectiveness and security of the two products under study, rucaparib and atezolizumab. It will thus assess whether these two drugs can not only stop the growth of tumour cells, but also activate the immune cells (lymphocytes) involved in the destruction of pathological cells.